Aardvark Therapeutics (NASDAQ:AARD) Issues Quarterly Earnings Results

Aardvark Therapeutics (NASDAQ:AARD) announced its earnings results on Tuesday. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21, Zacks reports.

Aardvark Therapeutics Stock Performance

Shares of AARD stock opened at $6.57 on Thursday. The firm has a market capitalization of $143.75 million, a price-to-earnings ratio of -2.05 and a beta of 3.81. The company has a 50 day moving average price of $5.54 and a 200 day moving average price of $6.55. Aardvark Therapeutics has a one year low of $3.35 and a one year high of $17.94.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. BTIG Research cut Aardvark Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. B. Riley Financial reduced their target price on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Weiss Ratings raised shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 2nd. HC Wainwright reissued a “neutral” rating and issued a $6.00 price objective on shares of Aardvark Therapeutics in a research report on Monday, July 20th. Finally, Morgan Stanley reissued an “underweight” rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $16.30.

Hedge Funds Weigh In On Aardvark Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Trexquant Investment LP acquired a new stake in shares of Aardvark Therapeutics in the fourth quarter worth $221,000. Diadema Partners LP purchased a new stake in Aardvark Therapeutics during the 4th quarter worth $208,000. Walleye Capital LLC acquired a new stake in Aardvark Therapeutics in the 4th quarter valued at $211,000. Wells Fargo & Company MN increased its holdings in Aardvark Therapeutics by 259.5% in the 4th quarter. Wells Fargo & Company MN now owns 14,080 shares of the company’s stock valued at $185,000 after purchasing an additional 10,163 shares in the last quarter. Finally, Alps Advisors Inc. purchased a new position in Aardvark Therapeutics in the fourth quarter valued at about $235,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (ROR?). ROR? plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective ROR? inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.